[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gram-negative-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gram-negative-infection":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100566120",false,"NCT06651047","PK\u002FPD Analysis of Ceftazidime\u002FAvibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","Pharmacokinetic\u002FPharmacodynamic Analysis of Ceftazidime\u002FAvibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","PACCOF","Inclusion Criteria:\n\n* Patients with infection due to a difficult-to-treat Gram-negative bacteria treated with CAZ\u002FAVI alone, CEF alone, CAZ\u002FAVI plus FOS, or CEF plus FOS (any age)\n* Signature of the informed consent (for pediatric patients: parents or guardians able to provide consent)\n\nExclusion Criteria:\n\n* Premature newborns\n* Polymicrobial\u002Fmixed infections with the exception of cases with multiple Gram-negative bacteria susceptible to study drugs\n* Continuous renal replacement therapy (CRRT) applications\n\nInclusion Criteria for Healthy Volunteer Subjects:\n\n* Age ≥18 years\n* Signature of the informed consent\n\nExclusion Criteria for Healthy Volunteer Subjects:\n\n\\- Any known clinically relevant health problems",true,"ALL",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","A multicenter, national, prospective, observational pharmacological study of patients with difficult-to-treat Gram-negative infections treated with ceftazidime\u002Favibactam (CAZ\u002FAVI) or cefiderocol (CEF) monotherapy or combination therapy with ceftazidime\u002Favibactam associated with fosfomycin (FOS) or cefiderocol associated with fosfomycin.",[24,25],"Gram Negative Infection","Antimicrobial Resistance (AMR)",[27,28,29,30,31,32],"Gram-negative infection","Ceftazidime\u002FAvibactam","Cefiderocol","Fosfomycin","Pharmacokinetics\u002FPharmacodynamics targets","Carbapenem-resistant Enterobacterales (CRE)","RECRUITING","2024-10-18",{"date":36,"type":37},"2024-10-21","ACTUAL",{"date":39,"type":37},"2024-07-09",{"date":41,"type":20},"2025-09-30",{"name":43,"class":44},"University of Bologna","OTHER",11,""]